Genomeweb: Economic Model Finds MammaPrint More Cost-Effective than Oncotype; Highlights Need for
In the study, researchers led by Amalia Issa of the University of the Sciences in Philadelphia developed a 10-year Markov model to compare the costs incurred and quality-adjusted life years gained when
oncologists used either Oncotype DX or MammaPrint to guide treatment decisions for a hypothetical cohort of 1,000 women with early-stage, estrogen receptor-positive breast cancer that hasn't spread to the lymph nodes.
